Aimei Health Technology Co., Ltd PRE 14A, filed Oct 9, 2026
Aimei Health Technology Co., Ltd. (AFJK)
Aimei Health seeks shareholder approval to extend its business-combination deadline from December 6, 2026 to December 6, 2027 after the United Hydrogen Group Inc. agreement was terminated on July 7, 2026. AI summary
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
Filed by the Registrant ☒
Filed by a Party other than the Registrant ☐
Check the appropriate box:
| ☒ | Preliminary Proxy Statement |
| ☐ | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
| ☐ | Definitive Proxy Statement |
| ☐ | Definitive Additional Materials |
| ☐ | Soliciting Material Pursuant to Section 240.14a-12 |
AIMEI HEALTH TECHNOLOGY CO., LTD
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
| Payment of Filing Fee (Check the appropriate box): | |
| ☒ | No fee required. |
| ☐ | Fee paid previously with preliminary materials. |
| ☐ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. |
AIMEI HEALTH TECHNOLOGY CO., LTD
10 East 53rd Street, Suite 3001
New York, NY 10022
+86 13758131392
NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS
TO BE HELD ON NOVEMBER 10, 2026
TO THE SHAREHOLDERS OF AIMEI HEALTH TECHNOLOGY CO., LTD:
You are cordially invited to attend the extraordinary general meeting of shareholders of Aimei Health Technology Co., Ltd (“Aimei Health,” “Company,” “we,” “us” or “our”) to be held on November 10, 2026 in person in the offices of the Company’s counsel, Hunter Taubman Fischer & Li LLC, at 950 Third Avenue, 19th Floor, New York, NY 10022 and virtually at 10:00 a.m. Eastern Time, or at such other time, on such other date and at such other place at which the meeting may be adjourned (the “Extraordinary General Meeting”).
If you plan on attending the Extraordinary General Meeting in person, please email xiejunheng@aimeihealth.com at least one day prior to the Extraordinary General Meeting. If you plan on attending the Extraordinary General Meeting online, you will be able to vote and submit your questions during the Extraordinary General Meeting by visiting https://www.virtualshareholdermeeting.com/AFJKU2026 shortly prior to the start of the meeting and entering the 16-digit control number found on the proxy card or voting instruction form. A person participating in the Extraordinary General Meeting in the virtual meeting format is deemed to be present in person at the meeting.
The purpose of the Extraordinary General Meeting will be to consider and vote on the following proposals:
| 1. | Proposal 1 – To approve, by special resolution, an amendment to the Amended and Restated Articles of Association of the Company currently in effect (the “Articles”), to extend the date by which the Company has to consummate a business combination from 36 months from the date of the Company’s initial public offering (namely, December 6, 2026) to 48 months from the date of the Company’s initial public offering (namely, December 6, 2027) (the “Article Amendment Proposal”);
The text of the special resolution is as follows:
“RESOLVED, as a special resolution, that with immediate effect, the Amended and Restated Articles of Association of the Company currently in effect (the “Articles”) be amended to extend the date by which the Company has to consummate a business combination from 36 months from the date of the Company’s initial public offering (namely, December 6, 2026) to 48 months from the date of the Company’s initial public offering (namely, December 6, 2027) by the deletion of the existing Article 35.2 in its entirety and the insertion of the following language in its place:
The Company has until 12 months from the closing of the IPO to consummate a Business Combination, provided however that if the board of directors anticipates that the Company may not be able to consummate a Business Combination within 12 months of the closing of the IPO, the Company may, by resolution of directors if requested by the Sponsor, extend the period of time to consummate a Business Combination up to thirty-six times, each by an additional one month (for a total of up to 48 months to complete a Business Combination), subject to the Sponsor depositing additional funds into the Trust Account in accordance with terms as set out in the trust agreement governing the Trust Account and referred to in the Registration Statement, or, if such trust agreement has been amended, in that trust agreement, as amended from time to time, in accordance with its terms. In the event that the Company does not consummate a Business Combination within 12 months from the closing of the IPO or within up to 48 months from the closing of the IPO (subject in the latter case to valid 1 month extensions having been made in each case (such date falling 12 months or up to 48 months, as applicable, after the closing of the IPO being referred to as the “Termination Date”)), such failure shall trigger an automatic redemption of the Public Shares (an “Automatic Redemption Event”) and the directors of the Company shall take all such action necessary to (i) cease all operations except for the purpose of winding up (ii) as promptly as reasonably possible but no more than five (5) Business Days thereafter to redeem the Public Shares to the holders of Public Shares, on a pro rata basis, in cash at a per-share amount equal to the applicable Per-Share Redemption Price; and (iii) as promptly as reasonably possible following such Automatic Redemption Event, subject to the approval of our remaining Members and our directors, liquidate and dissolve the Company, subject to the Company’s obligations under the Act to provide for claims of creditors and the requirements of other applicable law. In the event of an Automatic Redemption Event, only the holders of Public Shares shall be entitled to receive pro rata redeeming distributions from the Trust Account with respect to their Public Shares.” |
| 2. | Proposal 2 – To approve, by ordinary resolution, an amendment to the Investment Management Trust Agreement dated December 1, 2023 (as amended, the “Trust Agreement”), entered into by and between Continental Stock Transfer & Trust Company, as trustee (the “Trustee”) and the Company governing the trust account established in connection with the Company’s initial public offering (“IPO”), to clarify the extension of the date by which the Company has to consummate a business combination from 36 months from the date of the Company’s initial public offering, to 48 months from the date of the Company’s initial public offering (the “Trust Agreement Amendment Proposal”). | |
| 3. | Proposal 3 – To approve, by ordinary resolution, the engagement of MaloneBailey, LLP to serve as the Company’s independent registered public accounting firm for the year ending December 31, 2026 (the “Auditor Appointment Proposal”). | |
| 4. | Proposal 4 – To approve, by ordinary resolution, to direct the chairman of the Extraordinary General Meeting to adjourn the Extraordinary General Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies in the event there are not sufficient votes for, or otherwise in connection with, the approval of the foregoing proposals (the “Adjournment Proposal”). |
Each of the Article Amendment Proposal, the Trust Agreement Amendment Proposal, the Auditor Appointment Proposal, and the Adjournment Proposal (together the “Proposals”) is more fully described in the accompanying proxy statement. Each of the Proposals is not conditioned upon the approval of any other Proposal. Please take the time to read carefully each of the Proposals in the accompanying proxy statement before you vote.
The current Articles and the Trust Agreement provide that the Company has until 12 months from the closing of its IPO (“Combination Period”) to consummate its initial business combination (namely, until December 6, 2024). The current Articles and the Trust Agreement also provide that if the board of directors (the “Board”) anticipates that we may not be able to consummate our initial business combination within the Combination Period, we may, by resolution of the Board if requested by our sponsor, Aimei Investment Ltd (the “Sponsor”), extend the Combination Period up to twenty-four (24) times each for an additional one month (each, a “Monthly Extension”) from December 6, 2024 (i.e., 12 months after the consummation of the IPO) up to December 6, 2026 (i.e., 36 months after the consummation of the IPO) subject to the Sponsor depositing additional funds into the trust account (the “Trust Account”) established pursuant to the Trust Agreement, in accordance with the terms set out in that agreement and referred to in the Registration Statement (as that term is defined in the Articles). If the Article Amendment Proposal and Trust Agreement Amendment Proposal are approved by the shareholders, the Company will be granted an additional 12 months to consummate its business combination, thereby extending the Termination Date from December 6, 2026 to as late as December 6, 2027. To effectuate each subsequent Monthly Extension, the Sponsor will be required to deposit into the Trust Account an amount equal to the lesser of (i) $80,000 for all outstanding Public Shares and (ii) $0.033 for each outstanding Public Share, for each Monthly Extension (the “Monthly Extension Fee”). Each subsequent Monthly Extension Fee, if and to the extent the Trust Agreement Amendment Proposal is approved at the Extraordinary General Meeting, must be deposited into the Trust Account by the sixth of each succeeding month until November 6, 2027 (each, a “Contribution”, together “Contributions”) to effect each additional Monthly Extension. The amount of the Contributions will not bear interest and will be repayable by us to our Sponsor upon consummation of an initial business combination.
The purpose of the Article Amendment Proposal and the Trust Agreement Amendment Proposal is to allow the Company additional time to complete its initial business combination. The Company previously entered into a definitive business combination agreement (the “Business Combination Agreement” or “Merger Agreement”) with United Hydrogen Group Inc. (“United Hydrogen”), which was terminated on July 7, 2026 because the required approval from the China Securities Regulatory Commission (the “CSRC”) had not been obtained by United Hydrogen as of July 6, 2026. The Company delivered a notice of termination to United Hydrogen on July 7, 2026, pursuant to Section 9.1(b) of the Business Combination Agreement, effective immediately. As a result, the proposed business combination with United Hydrogen will not be consummated. The Board believes that there is insufficient time for the Company to identify and complete a new business combination before December 6, 2026. Accordingly, the Board believes that in order to be able to consummate a business combination, the Company will need to extend the Termination Date from 36 months from the date of the Company’s IPO (namely, December 6, 2026) to as late as 48 months from the date of the Company’s IPO (namely, December 6, 2027) (the “Extension”). Without the Extension, the Board believes that there is a significant risk that the Company will not, despite its best efforts, be able to complete a business combination on or before December 6, 2026. If that were to occur, the Company would be precluded from completing a business combination and would be forced to liquidate even if its shareholders are otherwise in favor of consummating a business combination. Therefore, the Board has determined that it is in the best interests of the Company to give effect to the proposed amendment to the Articles and recommends that our shareholders approve and adopt the Article Amendment Proposal.
The purpose of the Auditor Appointment Proposal is to give our shareholders the opportunity to approve the engagement of MaloneBailey, LLP to serve as the Company’s independent registered public accounting firm for the year ending December 31, 2026. The Board recommends our shareholders approve and adopt the Auditor Appointment Proposal.
The purpose of the Adjournment Proposal is to direct the chairman of the Extraordinary General Meeting to adjourn the Extraordinary General Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of the foregoing proposals. The Board recommends our shareholders approve and adopt the Adjournment Proposal.
If the Article Amendment Proposal is duly approved by a special resolution of our shareholders, Aimei Health will offer to redeem its ordinary shares sold in its IPO (“Public Shares”). No redemption of Public Shares shall be offered in the event that the Article Amendment Proposal is not approved. Holders (“Public Shareholders”) of Aimei Health’s Public Shares may elect to redeem their Public Shares for cash, on a pro rata basis, at a per-share amount equal to the aggregate amount of the funds available in the Trust Account, including interest earned but net of taxes payable, divided by the number of then outstanding Public Shares, upon the approval of the Article Amendment Proposal by a special resolution of our shareholders (the “Election”). A Public Shareholder may elect to redeem their Public Shares regardless of how such Public Shareholder voted in regard to the Proposals, or whether they were holders of Aimei Health’s ordinary shares on the Record Date (defined further below) or acquired such shares after such date. If the Article Amendment Proposal is duly approved by our shareholders, Aimei Health will offer to redeem the Public Shares held by the Public Shareholders electing to be redeemed, provided that Aimei Health shall not redeem ordinary shares held by our Initial Shareholders (as defined in the Articles) or their affiliates or the directors or officers of the Company pursuant to such offer, whether or not such holders accept such offer, in accordance with Article 35.11 of the Articles. If the Article Amendment Proposal is duly approved, Public Shareholders who do not make the Election will retain their right to redeem their Public Shares for cash, on a pro rata basis at a per-share amount equal to the aggregate amount of the funds available in the Trust Account on the date that is two Business Days (as defined in the Articles) prior to the consummation of a business combination, including interest earned but net of taxes payable, divided by the number of then outstanding Public Shares. In addition, if the Article Amendment Proposal is duly approved, Public Shareholders who do not make the Election will be entitled to have their Public Shares redeemed for cash, on a pro-rata basis, at a price per share amount equal to the aggregate amount on deposit in the Trust Account (including interest not previously released to us, which shall be net of taxes payable, and less interest to pay dissolution expenses) divided by the number of then outstanding Public Shares, if the Company has not completed the business combination by December 6, 2027, or by an earlier date if the Sponsor does not deposit the monthly extension fee required for the monthly extensions (the “Termination Date”).
To exercise your redemption rights upon approval of the Article Amendment Proposal, you must tender your shares to the Company’s transfer agent at least two business days prior to the Extraordinary General Meeting (or November 6, 2026). You may tender your shares by either delivering your share certificates to the transfer agent or by delivering your shares electronically using The Depository Trust Company’s DWAC (Deposit/Withdrawal At Custodian) system. If you hold your shares in street name, you will need to instruct your bank, broker or other nominee to withdraw the shares from your account in order to exercise your redemption rights.
The per-share pro rata portion of the Trust Account, including interest earned but net of taxes payable, was approximately $12.25 per Public Share as of October 2, 2026 (“Record Date”). The closing price of Aimei Health’s shares on the Record Date was $12.11. Aimei Health cannot assure shareholders that they will be able to sell their Public Shares in the open market, as there may not be sufficient liquidity in its securities when shareholders wish to sell their Public Shares.
The approval of the Article Amendment Proposal requires a special resolution which requires the affirmative vote of at least two-thirds of the votes cast by the shareholders who, being present in person or represented by proxy at the Extraordinary General Meeting and entitled to vote on such matter, vote at the Extraordinary General Meeting.
The approval of each of the Trust Agreement Amendment Proposal, the Auditor Appointment Proposal and the Adjournment Proposal requires an ordinary resolution which requires the affirmative vote of a simple majority of the votes cast by the shareholders who, being present in person or by proxy and entitled to vote at the Extraordinary General Meeting, vote at the Extraordinary General Meeting.
The Board has fixed the close of business on October 2, 2026 as the Record Date for the determination of shareholders entitled to notice of and to vote at the Extraordinary General Meeting. Only holders of record of Aimei Health’s ordinary shares on that date are entitled to notice of and to have their votes counted at the Extraordinary General Meeting.
After careful consideration of all relevant factors, the Board has determined that the Article Amendment Proposal, the Trust Agreement Amendment Proposal, the Auditor Appointment Proposal and the Adjournment Proposal are fair to and in the best interests of Aimei Health and its shareholders, has declared them advisable and recommends that you vote or give instruction to vote “FOR” all the foregoing Proposals.
Enclosed is the proxy statement containing detailed information concerning the Proposals and Extraordinary General Meeting. Whether or not you plan to attend the Extraordinary General Meeting, we urge you to read this material carefully and vote your shares.
We look forward to seeing you at the Extraordinary General Meeting.
Dated: [●], 2026
| By Order of the Board, | |
| Junheng Xie | |
| Chief Executive Officer | |
| Aimei Health Technology Co., Ltd |
Your vote is important. Each shareholder who is entitled to attend and vote at the Extraordinary General Meeting is entitled to appoint one or more proxies to attend and vote instead of that shareholder, and a proxyholder need not be a shareholder. Please sign, date, and return your proxy card as soon as possible to make sure that your shares are represented at the Extraordinary General Meeting. Your proxy card must be received not less than 48 hours before the time for holding the Extraordinary General Meeting. If you are a shareholder of record, you may also cast your vote in person or online at the Extraordinary General Meeting. If your shares are held in an account at a brokerage firm or bank, you must instruct your broker or bank how to vote your shares, or you may cast your vote in person or online at the Extraordinary General Meeting by obtaining a proxy from your brokerage firm or bank.
Important Notice Regarding the Availability of Proxy Materials for the Extraordinary General Meeting of Shareholders to be held on November 10, 2026: This Notice of Extraordinary General Meeting and the accompanying proxy statement are available at https://www.proxyvote.com by entering your unique 16-digit control number found in your proxy materials.
How to Vote
| ● | By Internet: During the Extraordinary General Meeting, you may vote online at https://www.virtualshareholdermeeting.com/AFJKU2026. | |
| ● | By Mail: You may vote by completing and returning the enclosed proxy card by mail to Vote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717. | |
| ● | In Person: All shareholders are cordially invited to attend the Extraordinary General Meeting in person. If you plan on attending the Extraordinary General Meeting in person, please email xiejunheng@aimeihealth.com at least one day prior to the Extraordinary General Meeting. |
This communication is not a form for voting and presents only an overview of the more complete proxy materials. The Company encourages you to review the complete proxy materials before voting. You will receive paper copies of all of our proxy materials by mail and can also access our proxy materials and our Annual Report on Form 10-K for the year ended December 31, 2025 online at www.proxyvote.com. The paper copies of all of our proxy materials are first being distributed or made available, as the case may be, to our shareholders on or about October 23, 2026.
PROXY STATEMENT FOR THE EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS
TO BE HELD ON NOVEMBER 10, 2026
This proxy statement, along with the accompanying Notice of Extraordinary General Meeting of Shareholders, contains information about the Extraordinary General Meeting of the Company, including any adjournments of the Extraordinary General Meeting. We are holding the Extraordinary General Meeting in person at the offices of Hunter Taubman Fischer & Li LLC at 950 Third Avenue, 19th Floor, New York, NY 10022 and virtually online at https:// www.virtualshareholdermeeting.com/AFJKU2026, on November 10, 2026, at 10:00 a.m., Eastern Time.
Capitalized terms used but not defined in this proxy statement have the meaning given to them in the accompanying Notice of Extraordinary General Meeting of Shareholders.
This proxy statement relates to the solicitation of proxies by the Board for use at the Extraordinary General Meeting.
This Notice of Extraordinary General Meeting and proxy statement are first being distributed or made available, as the case may be, to our shareholders on or about October 23, 2026. This proxy statement and our Annual Report on Form 10-K for the year ended December 31, 2025 are available at www.proxyvote.com and can be obtained, free of charge, by entering the 16-digit control number found in your proxy materials.
QUESTIONS AND ANSWERS ABOUT THE EXTRAORDINARY GENERAL MEETING
These questions and answers are only summaries of the matters they discuss. They do not contain all of the information that may be important to you. You should read carefully this entire proxy statement.
| Why am I receiving this proxy statement? | This proxy statement and the accompanying materials are being sent to you in connection with the solicitation of proxies by the Board, for use at the Extraordinary General Meeting to be held in person at the offices of Hunter Taubman Fischer & Li LLC, at 950 Third Avenue, 19th Floor, New York, NY 10022 and virtually online at https://www.virtualshareholdermeeting.com/AFJKU2026, on November 10, 2026 at 10:00 a.m., Eastern Time, or at any adjournments thereof. This proxy statement summarizes the information that you need to make an informed decision on the Proposals to be considered at the Extraordinary General Meeting. |
| What is being voted on? | You are being asked to consider and vote on the following Proposals: |
| ● | Article Amendment Proposal: a proposal to approve by special resolution an amendment to the Amended and Restated Articles of Association of the Company currently in effect (the “Articles”) to extend the date by which the Company has to consummate a business combination from 36 months from the date of the Company’s IPO (namely, December 6, 2026) to 48 months from the date of the Company’s IPO (namely, December 6, 2027); | |||
| ● | Trust Agreement Amendment Proposal: a proposal to approve, by ordinary resolution, an amendment to the Investment Management Trust Agreement dated December 1, 2023 (as amended, the “Trust Agreement”), entered into by and between Continental Stock Transfer & Trust Company, as trustee (the “Trustee”) and the Company governing the trust account established in connection with the Company’s initial public offering (“IPO”), to clarify the extension of the date by which the Company has to consummate a business combination from 36 months from the date of the Company’s initial public offering, to 48 months from the date of the Company’s initial public offering; | |||
| ● | Auditor Appointment Proposal: a proposal to approve by ordinary resolution the engagement of MaloneBailey, LLP to serve as the Company’s independent registered public accounting firm for the year ending December 31, 2026; and | |||
| ● | Adjournment Proposal: a proposal to approve by ordinary resolution to direct the chairman of the Extraordinary General Meeting to adjourn the Extraordinary General Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies in the event there are not sufficient votes for, or otherwise in connection with, the approval of the foregoing proposals. |
| How does the Board recommend I vote? | After careful consideration of all relevant factors, the Board recommends that you vote or give instruction to vote “FOR” the Article Amendment Proposal, “FOR” the Trust Agreement Amendment Proposal, “FOR” the Auditor Appointment Proposal, and “FOR” the Adjournment Proposal. |
| Why is the Company proposing the Proposals? | The existing Article 35.2 provides “The Company has until 12 months from the closing of the IPO to consummate a Business Combination, provided however that if the board of directors anticipates that the Company may not be able to consummate a Business Combination within 12 months of the closing of the IPO, the Company may, by resolution of directors if requested by the Sponsor, extend the period of time to consummate a Business Combination up to twenty-four times, each by an additional one month (for a total of up to 36 months to complete a Business Combination), subject to the Sponsor depositing additional funds into the Trust Account in accordance with terms as set out in the trust agreement governing the Trust Account and referred to in the Registration Statement, or, if such trust agreement has been amended, in that trust agreement, as amended from time to time, in accordance with its terms. In the event that the Company does not consummate a Business Combination within 12 months from the closing of the IPO or within up to 36 months from the closing of the IPO (subject in the latter case to valid 1 month extensions having been made in each case (such date falling 12 months or up to 36 months, as applicable, after the closing of the IPO being referred to as the Termination Date)), such failure shall trigger an automatic redemption of the Public Shares (an Automatic Redemption Event) and the directors of the Company shall take all such action necessary to (i) cease all operations except for the purpose of winding up (ii) as promptly as reasonably possible but no more than five (5) Business Days thereafter to redeem the Public Shares to the holders of Public Shares, on a pro rata basis, in cash at a per-share amount equal to the applicable Per-Share Redemption Price; and (iii) as promptly as reasonably possible following such Automatic Redemption Event, subject to the approval of our remaining Members and our directors, liquidate and dissolve the Company, subject to the Company’s obligations under the Act to provide for claims of creditors and the requirements of other applicable law. In the event of an Automatic Redemption Event, only the holders of Public Shares shall be entitled to receive pro rata redeeming distributions from the Trust Account with respect to their Public Shares.”
The proposed amendment to Article 35.2 is to extend the date by which the Company has to consummate a business combination from 36 months from the date of the Company’s initial public offering (namely, December 6, 2026) to 48 months from the date of the Company’s initial public offering (namely, December 6, 2027) so that Article 35.2 will be amended to provide as follows: “The Company has until 12 months from the closing of the IPO to consummate a Business Combination, provided however that if the board of directors anticipates that the Company may not be able to consummate a Business Combination within 12 months of the closing of the IPO, the Company may, by resolution of directors if requested by the Sponsor, extend the period of time to consummate a Business Combination up to thirty-six times, each by an additional one month (for a total of up to 48 months to complete a Business Combination), subject to the Sponsor depositing additional funds into the Trust Account in accordance with terms as set out in the trust agreement governing the Trust Account and referred to in the Registration Statement, or, if such trust agreement has been amended, in that trust agreement, as amended from time to time, in accordance with its terms. In the event that the Company does not consummate a Business Combination within 12 months from the closing of the IPO or within up to 48 months from the closing of the IPO (subject in the latter case to valid 1 month extensions having been made in each case (such date falling 12 months or up to 48 months, as applicable, after the closing of the IPO being referred to as the Termination Date)), such failure shall trigger an automatic redemption of the Public Shares (an Automatic Redemption Event) and the directors of the Company shall take all such action necessary to (i) cease all operations except for the purpose of winding up (ii) as promptly as reasonably possible but no more than five (5) Business Days thereafter to redeem the Public Shares to the holders of Public Shares, on a pro rata basis, in cash at a per-share amount equal to the applicable Per-Share Redemption Price; and (iii) as promptly as reasonably possible following such Automatic Redemption Event, subject to the approval of our remaining Members and our directors, liquidate and dissolve the Company, subject to the Company’s obligations under the Act to provide for claims of creditors and the requirements of other applicable law. In the event of an Automatic Redemption Event, only the holders of Public Shares shall be entitled to receive pro rata redeeming distributions from the Trust Account with respect to their Public Shares.” |
If the Article Amendment Proposal is duly approved by a special resolution of our shareholders, Aimei Health will offer to redeem the Public Shares held by the Public Shareholders electing to be redeemed, and shall not redeem ordinary shares held by our Initial Shareholders or their affiliates or the directors or officers of the Company pursuant to such offer, whether or not such holders accept such offer, in accordance with Article 35.11 of the Articles. No redemption of Public Shares shall be offered in the event that the Article Amendment Proposal is not approved.
The current Articles and the Trust Agreement provide that the Company has until 12 months from the closing of its IPO to consummate our initial business combination (i.e., until December 6, 2024). The current Articles and the Trust Agreement also provide that if the Board anticipates that we may not be able to consummate our initial business combination within the Combination Period, we may, by resolution of the Board if requested by our Sponsor, extend the Combination Period up to twenty-four (24) times each for an additional one month from December 6, 2024 (i.e., 12 months after the consummation of the IPO) to as late as December 6, 2026 (i.e., 36 months after the consummation of the IPO), subject to the Sponsor depositing additional funds into the Trust Account established pursuant to the Trust Agreement, in accordance with the terms set out in that agreement and referred to in the Registration Statement (as that term is defined in the Articles).
If the Article Amendment Proposal and the Trust Agreement Amendment Proposal are approved by the shareholders, the Company will be granted an additional 12 months to consummate its business combination, thereby extending the Termination Date from December 6, 2026 to as late as December 6, 2027. The Sponsor will be required to deposit an amount equal to the lesser of (i) $80,000 for all outstanding Public Shares and (ii) $0.033 for each outstanding Public Share into the Trust Account, for each Monthly Extension until November 6, 2027.
If the Auditor Appointment Proposal is approved by the shareholders, the engagement of MaloneBailey, LLP to serve as the Company’s independent registered public accounting firm for the year ending December 31, 2026 will be approved.
If the Adjournment Proposal is approved by the shareholders, the Company will be allowed more time to solicit additional proxies in favor of the foregoing proposals, in the event there are not sufficient votes for, or otherwise in connection with, the approval of the foregoing proposals. |
| Why should I vote for the Proposals? | The Board believes that the approval of Article Amendment Proposal will provide the Company with greater flexibility and the potential to reduce the costs associated with the initial business combination as disclosed in our current filings with the SEC. The Board believes that the approval of Article Amendment Proposal is necessary to facilitate the consummation of the initial business combination. Therefore, the Board has determined that it is in the best interests of the Company to give effect to the proposed amendment to the Articles and recommends our shareholders approve and adopt the Article Amendment Proposal. | |
If the Article Amendment Proposal is duly approved by a special resolution of our shareholders, Aimei Health will offer to redeem the Public Shares held by the Public Shareholders electing to be redeemed in accordance with Article 35.11 of the Articles. No redemption of Public Shares shall be offered in the event that the Article Amendment Proposal is not approved.
The Board believes that the approval of the Article Amendment Proposal and the Trust Agreement Amendment Proposal will allow the Company additional time to complete its initial business combination. The Board believes that the Article Amendment Proposal and the Trust Agreement Amendment Proposal are necessary in order to be able to consummate an initial business combination within the Combination Period. Therefore, the Board has determined that it is in the best interests of the Company to give effect to the proposed amendment to the Articles and the Trust Agreement and recommends our shareholders approve and adopt the Article Amendment Proposal and the Trust Agreement Amendment Proposal.
The purpose of the Auditor Appointment Proposal is to give our shareholders the opportunity to approve the engagement of MaloneBailey, LLP to serve as the Company’s independent registered public accounting firm for the year ending December 31, 2026. However, if our shareholders do not approve the selection of MaloneBailey, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026, the Board and audit committee may reconsider the selection of MaloneBailey, LLP as our independent registered public accounting firm. MaloneBailey, LLP has served as the Company’s independent registered public accounting firm since 2023. The Board recommends our shareholders approve and adopt the Auditor Appointment Proposal. | ||
| If the Adjournment Proposal is not approved by the Company’s shareholders, the chairman will not be able to adjourn the Extraordinary General Meeting to a later date or dates to approve the foregoing proposals. The Board recommends our shareholders approve and adopt the Adjournment Proposal. | ||
| How do the Aimei Health insiders intend to vote their shares? | All of Aimei Health’s directors and officers, its Sponsor and their respective affiliates are expected to vote any ordinary shares over which they have voting control (including any Public Shares owned by them) in favor of the Proposals.
Aimei Health’s directors and officers, its Sponsor, and their respective affiliates are not entitled to redeem the founder shares which include 1,725,000 ordinary shares initially issued to Aimei Investment Ltd for an aggregate purchase price of $25,000 (the “Founder Shares”) or the ordinary shares underlying the Private Units (as defined below). On the Record Date, Aimei Health’s directors, executive officers, its Sponsor and their respective affiliates beneficially owned and were entitled to vote 1,725,000 Founder Shares and 332,000 Private Units, representing approximately 64.96% of Aimei Health’s issued and outstanding ordinary shares.
Aimei Health’s directors, executive officers, its Sponsor and their respective affiliates may choose to buy Public Shares in the open market and/or through negotiated private purchases. In the event that purchases do occur, the purchasers may seek to purchase Public Shares from shareholders who would otherwise have voted against the Proposals. Any Public Shares held by or subsequently purchased by affiliates of Aimei Health may be voted in favor of the Proposals. |
| What if I do not want to vote “FOR” the Proposals? | If you do not want the Article Amendment Proposal, the Trust Agreement Amendment Proposal, the Auditor Appointment Proposal or the Adjournment Proposal to be approved, you may “ABSTAIN,” not vote, or vote “AGAINST” such proposal.
If you attend the Extraordinary General Meeting in person or by proxy, you may vote “AGAINST” any of the Proposals, and your ordinary shares will be counted for the purposes of determining whether the Proposals are approved.
However, if you fail to attend the Extraordinary General Meeting in person or by proxy, or if you do attend the Extraordinary General Meeting in person or by proxy but you “ABSTAIN” or otherwise fail to vote at the Extraordinary General Meeting, your ordinary shares will not be counted for the purposes of determining whether each of the Article Amendment Proposal, the Trust Agreement Amendment Proposal, the Auditor Appointment Proposal or the Adjournment Proposal is approved, and your ordinary shares which are not voted at the Extraordinary General Meeting will have no effect on the outcome of such vote. | |
| How do I change my vote? | If you have submitted a proxy to vote your shares and wish to change your vote, you may do so by delivering a later-dated, signed proxy card so as to be received at least 48 hours prior to the time for holding the Extraordinary General Meeting, or by voting in person or online at the Extraordinary General Meeting. Attendance at the Extraordinary General Meeting alone will not change your vote. You must follow the voting instructions included with the enclosed proxy card. |
| If my shares are held in “street name,” will my broker automatically vote them for me? | Broker non-votes occur when beneficial owners do not give voting instructions to their brokers and the brokers lack the discretionary authority to vote on the proposal. If you are a beneficial owner and do not give instructions to your broker, the broker will determine if it has the discretionary authority to vote on the particular matter.
Under the rules of the New York Stock Exchange, which are also applicable to companies listed on the Nasdaq Global Market (“Nasdaq”), brokers have the discretion to vote on routine matters such as ratifying the appointment of external auditors, but do not have discretion to vote on non-routine matters such as the election of directors and approving equity awards plans. We believe that each of the Article Amendment Proposal and Trust Agreement Amendment Proposal is a “non-routine” item. Your broker can vote your shares with respect to “non-routine items” only if you provide instructions on how to vote. You should instruct your broker to vote your shares. Your broker can tell you how to provide these instructions. If you do not give your broker instructions, your shares will be treated as broker non-votes, which will be counted for purposes of calculating whether a quorum is present at the meeting but will not be treated as votes cast and will have no effect on the Article Amendment Proposal or the Trust Agreement Amendment Proposal. |
| What is a quorum requirement? | A quorum of shareholders is necessary to hold a valid Extraordinary General Meeting. A quorum will be present for the Extraordinary General Meeting if the holders of a majority of the issued and outstanding shares are present in person or by proxy (or if a shareholder is a corporation or other non-natural person, by its duly authorized representative or proxy) at the Extraordinary General Meeting.
We will include abstentions and broker non-votes to determine whether a quorum is present at the Extraordinary General Meeting. If a quorum is not present within 15 minutes of the time appointed for the Extraordinary General Meeting, or if at any time during the meeting it becomes inquorate, then the meeting will automatically be adjourned to the same time and place seven days hence, or to such other time or place as is determined by the directors. If a quorum is not present within 15 minutes of the time appointed for the adjourned meeting, then the meeting shall be dissolved. |
| What vote is required to adopt each Proposal and how are votes counted? | The approval of the Article Amendment Proposal requires a special resolution which requires the affirmative vote of at least two-thirds of the votes cast by the shareholders, who, being present in person or represented by proxy at the Extraordinary General Meeting and entitled to vote on such matter, vote at the Extraordinary General Meeting.
The approval of each of the Trust Agreement Amendment Proposal, the Auditor Appointment Proposal and the Adjournment Proposal requires an ordinary resolution which requires the affirmative vote of a simple majority of the votes cast by the shareholders who, being present in person or by proxy and entitled to vote at the Extraordinary General Meeting, vote at the Extraordinary General Meeting. The Adjournment Proposal will only be put forth for a vote if there are not sufficient votes for, or otherwise in connection with, the approval of the Article Amendment Proposal at the Extraordinary General Meeting.
For purposes of the Article Amendment Proposal and the Trust Agreement Amendment Proposal, abstentions and broker non-votes, while considered present for the purposes of establishing a quorum, will not count as a vote cast at the Extraordinary General Meeting and will have no effect on the outcome of any vote on the Article Amendment Proposal or the Trust Agreement Amendment Proposal.
For purposes of the Auditor Appointment Proposal and the Adjournment Proposal, abstentions (but not broker non-votes), while considered present for the purposes of establishing a quorum, will not count as a vote cast at the Extraordinary General Meeting and will have no effect on the outcome of any vote on the Adjournment Proposal. |
| Who can vote at the Extraordinary General Meeting? | Only holders of record of Aimei Health’s ordinary shares at the close of business on the Record Date are entitled to have their vote counted at the Extraordinary General Meeting. On the Record Date, 3,166,332 ordinary shares were issued and outstanding and entitled to vote.
Shareholder of Record: Shares Registered in Your Name. If on the Record Date, your shares were registered directly in your name with Aimei Health’s Transfer Agent, Continental Stock Transfer & Trust Company, then you are a shareholder of record. As a shareholder of record, you may vote in person or online at the Extraordinary General Meeting or vote by proxy. Whether or not you plan to attend the Extraordinary General Meeting, we urge you to fill out and return the enclosed proxy card as soon as possible so that it is received not less than 48 hours before the time for holding the Extraordinary General Meeting to ensure your vote is counted.
Beneficial Owner: Shares Registered in the Name of a Broker or Bank. If on the Record Date, your shares were held, not in your name, but rather in an account at a brokerage firm, bank, dealer, or other similar organization, then you are the beneficial owner of shares held in “street name” and these proxy materials are being forwarded to you by that organization. As a beneficial owner, you have the right to direct your broker or other agent on how to vote the shares in your account. You are also invited to attend the Extraordinary General Meeting in person. However, since you are not the shareholder of record, you may not vote your shares online or in person at the Extraordinary General Meeting unless you request and obtain a valid proxy from your broker or other agent. |
| Does the Board recommend voting for the approval of the Proposals? | Yes. After careful consideration of the terms and conditions of these Proposals, the Board has determined that the Article Amendment Proposal, the Trust Agreement Amendment Proposal, the Auditor Appointment Proposal and the Adjournment Proposal are in the best commercial interests of Aimei Health. The Board recommends that Aimei Health’s shareholders vote “FOR” for the Article Amendment Proposal, the Trust Agreement Amendment Proposal, the Auditor Appointment Proposal and the Adjournment Proposal.
| |
| What interests do the Company’s sponsor, directors and officers have in the approval of the proposals? | Aimei Health’s directors, officers, its Sponsor and their respective affiliates have interests in the Proposals that may be different from, or in addition to, your interests as a shareholder. These interests include direct or indirect ownership of certain securities of the Company. See the section entitled “The Article Amendment Proposal — Interests of our Sponsor, Directors, and Officers.” | |
| Do I have appraisal rights if I object to the Proposals? | Our shareholders do not have appraisal rights in connection with any of the Proposals under Cayman Islands law. | |
| If the Article Amendment Proposal and the Trust Agreement Amendment Proposal are not approved, what happens next? | If the Article Amendment Proposal and the Trust Agreement Amendment proposal are not approved, we will not offer to redeem the Public Shares held by the Public Shareholders in accordance with Article 35.11 of the Articles and, if we are unable to complete our initial business combination by December 6, 2026, we will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than five business days thereafter, redeem 100% of the outstanding Public Shares which redemption will completely extinguish Public Shareholders’ rights as shareholders (including the right to receive further liquidation distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of our remaining holders of ordinary shares and the Board, proceed to commence a voluntary liquidation and thereby a formal dissolution of the company, subject (in the case of (ii) and (iii) above) to our obligations to provide for claims of creditors and the requirements of applicable law. Public Shareholders will retain their right to redeem their Public Shares for cash, on a pro-rata basis at a per-share amount equal to the aggregate amount of the funds available in the Trust Account on the date that is two Business Days prior to the consummation of a business combination, including interest earned but net of taxes payable, divided by the number of then outstanding Public Shares, or to have their Public Shares redeemed for cash, on a pro-rata basis, at a price per share amount equal to the aggregate amount on deposit in the Trust Account (including interest not previously released to us, which shall be net of taxes payable, and less interest to pay dissolution expenses) divided by the number of then outstanding Public Shares, if the Company has not completed the business combination by the Termination Date. |
| If the Article Amendment Proposal and the Trust Agreement Amendment Proposal are approved, what happens next? | If the Article Amendment Proposal is duly approved by a special resolution of our shareholders, Aimei Health will proceed to effect the proposed amendment and offer to redeem the Public Shares held by the Public Shareholders electing to be redeemed, and shall not redeem ordinary shares held by our Initial Shareholders or their affiliates or the directors or officers of the Company pursuant to such offer, whether or not such holders accept such offer, in accordance with Article 35.11 of the Articles. | |
| In addition, if the Article Amendment Proposal and the Trust Agreement Amendment Proposal are approved, the Company will be granted an additional 12 months to consummate its business combination, thereby extending the Termination Date from December 6, 2026 to as late as December 6, 2027. And for each Monthly Extension, our Sponsor will be required to deposit into the Trust Account the Monthly Extension Fee, equal to the lesser of (i) $80,000 for all outstanding Public Shares and (ii) $0.033 for each outstanding Public Share, to extend the date which the Company must consummate its initial business combination. |
| What do I need to do now? | Aimei Health urges you to read carefully and consider the information contained in this proxy statement and to consider how the Proposals will affect you as a Aimei Health shareholder. You should then vote as soon as possible in accordance with the instructions provided in this proxy statement and on the enclosed proxy card. | |
| How do I vote? | If you are a holder of record of Aimei Health’s ordinary shares, you may vote in person or online at the Extraordinary General Meeting or by submitting a proxy for the Extraordinary General Meeting. Whether or not you plan to attend the Extraordinary General Meeting in person or online, we urge you to vote by proxy to ensure your vote is counted. You may submit your proxy by completing, signing, dating and returning the enclosed proxy card in the accompanying pre-addressed postage-paid envelope so that it is received not less than 48 hours before the time for holding the Extraordinary General Meeting. You may still attend the Extraordinary General Meeting and vote in person or online if you have already voted by proxy. If your ordinary shares of Aimei Health are held in “street name” by a broker or other agent, you have the right to direct your broker or other agent on how to vote the shares in your account. You are also invited to attend the Extraordinary General Meeting in person or online. However, since you are not the shareholder of record, you may not vote your shares in person or online at the Extraordinary General Meeting unless you request and obtain a valid proxy from your broker or other agent. |
| How do I exercise my redemption rights? | If the Article Amendment Proposal is duly approved by special resolution of our shareholders, each Public Shareholder may seek to redeem all or a portion of its Public Shares at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest (which interest shall be net of taxes payable), divided by the number of then outstanding Public Shares. You will also be able to redeem your Public Shares in connection with any shareholder vote to approve a proposed business combination, or if the Company has not consummated a business combination by December 6, 2027, or by an earlier date if the Sponsor does not deposit the monthly extension fee required for the monthly extensions. In order to exercise your redemption rights in connection with the Article Amendment Proposal, you must, prior to 5:00 p.m. Eastern time on November 6, 2026 (two business days before the Extraordinary General Meeting) tender your shares physically or electronically and submit a request in writing that we redeem your Public Shares for cash to Continental Stock Transfer & Trust Company, our transfer agent, at the following address:
Continental Stock Transfer & Trust Company 1 State Street Plaza, 30th Floor New York, New York 10004 Attn: SPAC Redemption Team E-mail: spacredemptions@continentalstock.com
The redemption rights include the requirement that a shareholder must identify itself in writing as a beneficial holder and provide its legal name, phone number and address in order to validly redeem its Public Shares. |
| What should I do if I receive more than one set of voting materials? | You may receive more than one set of voting materials, including multiple copies of this proxy statement and multiple proxy cards or voting instruction cards, if your shares are registered in more than one name or are registered in different accounts. For example, if you hold your shares in more than one brokerage account, you will receive a separate voting instruction card for each brokerage account in which you hold shares. Please complete, sign, date and return each proxy card and voting instruction card that you receive so that it is received not less than 48 hours before the time for holding the Extraordinary General Meeting, in order to cast a vote with respect to all of your ordinary shares of Aimei Health. | |
| Who can help answer my questions? | If you have questions about the Proposals, or if you need additional copies of the proxy statement or the enclosed proxy card, you should contact:
Aimei Health Technology Co., Ltd 10 East 53rd Street, Suite 3001 New York, NY 10022 +86 13758131392
You may also obtain additional information about the Company from documents filed with the SEC by following the instructions in the section entitled “Where You Can Find More Information.” |
FORWARD-LOOKING STATEMENTS
This proxy statement contains statements that are forward-looking and as such are not historical facts. These include, without limitation, statements regarding the Company’s financial position, business strategy and the plans and objectives of management for future operations, including as they relate to a business combination. These statements constitute projections, forecasts and forward-looking statements, and are not guarantees of performance. They involve known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by these statements.
Such statements can be identified by the fact that they do not relate strictly to historical or current facts. When used in this proxy statement, words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “strive,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. When the Company discusses its strategies or plans, including as they relate to a business combination, it is making projections, forecasts or forward-looking statements. Forward-looking statements are based on the opinions, estimates and beliefs of the Company’s management as of the date such statements are made, as well as assumptions made by and information currently available to the Company’s management, and they are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to:
| ● | our ability to obtain approval for the Proposals; | |
| ● | our ability to complete the initial business combination; | |
| ● | the amount of redemptions by our public shareholders; | |
| ● | the market price and liquidity of our public securities; | |
| ● | the per-share redemption price; or | |
| ● | the Trust Account being subject to claims of third parties. |
Additional information on these and other factors that may cause actual results and the Company’s performance to differ materially is included in the IPO Prospectus and the Company’s periodic reports filed with the SEC, including but not limited to the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, including those factors described under the “Item 1A. Risk Factors” therein, the Company’s subsequent Quarterly Reports on Form 10-Q, this proxy statement and other reports filed by Aimei Health with the SEC. Copies of the Company’s filings with the SEC are available publicly on SEC’s website at http://www.sec.gov or may be obtained by contacting the Company.
Many of the risks and factors that will determine these results and shareholders’ value are beyond the Company’s ability to control or predict. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made.
All forward-looking statements are made only as of the date of this proxy statement. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. All subsequent written or oral forward-looking statements attributable to us or persons acting on the Company’s behalf are qualified in their entirety by this “Forward-Looking Statements” section.
BACKGROUND
We are a blank check company incorporated as a Cayman Islands exempted company with limited liability for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities, which we refer to throughout this document as our initial business combination.
On December 6, 2023, we consummated our IPO of 6,000,000 units (the “Public Units”). Each Public Unit consists of one ordinary share, $0.0001 par value, and one right (“Public Right”) to receive one-fifth (1/5) of one ordinary share upon the consummation of an initial business combination. The Public Units were sold at an offering price of $10.00 per Unit, generating gross proceeds of $60,000,000. Pursuant to that certain underwriting agreement, dated December 1, 2023, we granted Spartan Capital Securities, LLC, the representative of the underwriters, a 45-day option to purchase up to an additional 900,000 Public Units (over and above the 6,000,000 units referred to above) solely to cover over-allotments, if any (the “Over-Allotment Option”). Simultaneously with the consummation of our IPO, the underwriters exercised the Over-Allotment Option in full, generating total proceeds of $9,000,000.
Simultaneously with the closing of the IPO on December 6, 2023, we consummated the private placement (“Private Placement”) with our Sponsor, Aimei Investment Ltd, of 332,000 units (the “Private Units”), generating total proceeds of $3,320,000. The Private Units are identical to the Public Units sold in our IPO, except that the Private Units (including the underlying securities) may not, subject to certain limited exceptions, be transferred, assigned, or sold by it until six months after the completion of our initial business combination.
On December 6, 2023, a total of $69,690,000 of the net proceeds from the sale of Units in the IPO and the Private Placement, were placed in a U.S.-based trust account at Continental Stock Transfer & Trust Company, as trustee. This amount was comprised of proceeds of $69,000,000 in gross proceeds (which amount includes $690,000 of the underwriters’ deferred discount) from the IPO (including the proceeds received from the exercise by the underwriters of the over-allotment option), and a total of $3,320,000 in gross proceeds for the sale of the Private Units, offset by $1,930,000 in total offering expenses and $700,000 in use of proceeds not held in the Trust Account, which became available to be used to provide for business, legal and accounting due diligence on prospective business combinations, and continuing general and administrative expenses.
On December 3, 2023, the Units commenced trading on Nasdaq under the symbol “AFJKU.” Commencing January 22, 2024, the Company’s ordinary shares and Rights are separately traded on Nasdaq under the symbols “AFJK” and “AFJKR,” respectively.
On June 19, 2024, Aimei Health entered into the Business Combination Agreement for a business combination with (i) United Hydrogen Group Inc., an exempted company incorporated with limited liability in the Cayman Islands (“United Hydrogen”), (ii) United Hydrogen Global Inc., an exempted company incorporated with limited liability in the Cayman Islands (“Pubco”), (iii) United Hydrogen Victor Limited, an exempted company incorporated with limited liability in the Cayman Islands and a wholly-owned subsidiary of Pubco; (iv) United Hydrogen Worldwide Limited, an exempted company incorporated with limited liability in the Cayman Islands and a wholly-owned subsidiary of Pubco; and (v) Aimei Investment Ltd, a Cayman Islands exempted company, and the Company’s sponsor (the “Sponsor”), in the capacity as, from and after the closing of the transactions contemplated by the Merger Agreement (the “Closing”), the representative for Aimei Health and its shareholders. On November 6, 2025, the Company convened an extraordinary general meeting of shareholders, at which Aimei Health’s shareholders approved the proposed business combination with United Hydrogen. The completion of the proposed business combination was subject, among other conditions, to United Hydrogen obtaining required approvals from the China Securities Regulatory Commission (the “CSRC”). As of July 6, 2026, the CSRC had not granted such approval. On July 7, 2026, the Company delivered to United Hydrogen a notice of termination of the Business Combination Agreement pursuant to Section 9.1(b) thereof, effective the same day. As a result, the Business Combination Agreement terminated in accordance with its terms, and the proposed business combination with United Hydrogen will not be consummated. As of the date of this proxy statement, the Company is actively seeking and evaluating potential targets for a new business combination.
The mailing address of Aimei Health’s principal executive office is 10 East 53rd Street, Suite 3001, New York, NY 10022, and its telephone number is +86 13758131392.
You are not being asked to vote on a business combination at this time. If the Article Amendment Proposal is approved and you do not elect to redeem your Public Shares, you will retain the right to vote on any proposed business combination if and when it is submitted to shareholders and the right to redeem your Public Shares for a pro rata portion of the trust account in the event such business combination is approved and completed or the Company has not consummated a business combination by the Termination Date.
RISK FACTORS
You should consider carefully all of the risks described in our final prospectus for our IPO as filed with the SEC on December 5, 2023, the Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed with the SEC on May 4, 2026, and in the other reports we file with the SEC before making a decision to invest in our securities. Furthermore, if any of the events described in our final prospectus or other reports filed with the SEC occur, our business, financial condition and operating results may be materially adversely affected or we could face liquidation. In that event, the trading price of our securities could decline, and you could lose all or part of your investment. The risks and uncertainties described in our final prospectus and other reports are not the only ones we face. Additional risks and uncertainties that we are unaware of, or that we currently believe are not material, may also become important factors that adversely affect our business, financial condition and operating results or result in our liquidation. The operation of redemptions during any extended period may be affected if the Company’s IPO securities are no longer listed on a Designated Stock Exchange.
PROPOSAL 1 — THE ARTICLE AMENDMENT PROPOSAL
The existing Article 35.2 of the Company’s current articles of association provides “The Company has until 12 months from the closing of the IPO to consummate a Business Combination, provided however that if the board of directors anticipates that the Company may not be able to consummate a Business Combination within 12 months of the closing of the IPO, the Company may, by resolution of directors if requested by the Sponsor, extend the period of time to consummate a Business Combination up to twenty-four times, each by an additional one month (for a total of up to 36 months to complete a Business Combination), subject to the Sponsor depositing additional funds into the Trust Account in accordance with terms as set out in the trust agreement governing the Trust Account and referred to in the Registration Statement, or, if such trust agreement has been amended, in that trust agreement, as amended from time to time, in accordance with its terms. In the event that the Company does not consummate a Business Combination within 12 months from the closing of the IPO or within up to 36 months from the closing of the IPO (subject in the latter case to valid 1 month extensions having been made in each case (such date falling 12 months or up to 36 months, as applicable, after the closing of the IPO being referred to as the Termination Date)), such failure shall trigger an automatic redemption of the Public Shares (an Automatic Redemption Event) and the directors of the Company shall take all such action necessary to (i) cease all operations except for the purpose of winding up (ii) as promptly as reasonably possible but no more than five (5) Business Days thereafter to redeem the Public Shares to the holders of Public Shares, on a pro rata basis, in cash at a per-share amount equal to the applicable Per-Share Redemption Price; and (iii) as promptly as reasonably possible following such Automatic Redemption Event, subject to the approval of our remaining Members and our directors, liquidate and dissolve the Company, subject to the Company’s obligations under the Act to provide for claims of creditors and the requirements of other applicable law. In the event of an Automatic Redemption Event, only the holders of Public Shares shall be entitled to receive pro rata redeeming distributions from the Trust Account with respect to their Public Shares.”
The proposed amendment to Article 35.2 is to extend the Termination Date from 36 months from the date of the Company’s initial public offering (namely, December 6, 2026) to 48 months from the date of the Company’s initial public offering (namely, December 6, 2027), so that Article 35.2 will be amended to provide as follows: “The Company has until 12 months from the closing of the IPO to consummate a Business Combination, provided however that if the board of directors anticipates that the Company may not be able to consummate a Business Combination within 12 months of the closing of the IPO, the Company may, by resolution of directors if requested by the Sponsor, extend the period of time to consummate a Business Combination up to thirty-six times, each by an additional one month (for a total of up to 48 months to complete a Business Combination), subject to the Sponsor depositing additional funds into the Trust Account in accordance with terms as set out in the trust agreement governing the Trust Account and referred to in the Registration Statement, or, if such trust agreement has been amended, in that trust agreement, as amended from time to time, in accordance with its terms. In the event that the Company does not consummate a Business Combination within 12 months from the closing of the IPO or within up to 48 months from the closing of the IPO (subject in the latter case to valid 1 month extensions having been made in each case (such date falling 12 months or up to 48 months, as applicable, after the closing of the IPO being referred to as the Termination Date)), such failure shall trigger an automatic redemption of the Public Shares (an Automatic Redemption Event) and the directors of the Company shall take all such action necessary to (i) cease all operations except for the purpose of winding up (ii) as promptly as reasonably possible but no more than five (5) Business Days thereafter to redeem the Public Shares to the holders of Public Shares, on a pro rata basis, in cash at a per-share amount equal to the applicable Per-Share Redemption Price; and (iii) as promptly as reasonably possible following such Automatic Redemption Event, subject to the approval of our remaining Members and our directors, liquidate and dissolve the Company, subject to the Company’s obligations under the Act to provide for claims of creditors and the requirements of other applicable law. In the event of an Automatic Redemption Event, only the holders of Public Shares shall be entitled to receive pro rata redeeming distributions from the Trust Account with respect to their Public Shares.”
The Board’s Reasons for the Article Amendment Proposal
The Board believes that the approval of Article Amendment Proposal will allow the Company additional time to complete its initial business combination.
The Board believes that the approval of Article Amendment Proposal will allow the Company additional time to complete its initial business combination. As previously disclosed, on June 19, 2024, Aimei Health entered into the Merger Agreement for a business combination with United Hydrogen. On November 6, 2025, the Company convened an extraordinary general meeting of shareholders, at which Aimei Health’s shareholders approved the proposed business combination with United Hydrogen. The completion of the proposed business combination was subject, among other conditions, to United Hydrogen obtaining required approvals from the CSRC. As of July 6, 2026, the CSRC had not granted such approval. On July 7, 2026, the Company delivered to United Hydrogen a notice of termination of the Merger Agreement pursuant to Section 9.1(b) thereof, effective the same day. As a result, the Merger Agreement terminated in accordance with its terms, and the proposed business combination with United Hydrogen will not be consummated. As of the date of this proxy statement, Aimei Health is actively seeking and evaluating potential targets for a new business combination. The Board believes that there is no sufficient time for the Company to identify and complete a new business combination before December 6, 2026. Therefore, the Board believes that the approval of Article Amendment Proposal is necessary to facilitate the consummation of an initial business combination. Therefore, the Board has determined that it is in the best interests of the Company to give effect to the proposed amendment to the Articles and recommends our shareholders approve and adopt the Article Amendment Proposal.
The Board has approved and declared advisable adoption of the Article Amendment Proposal and recommends that you vote “FOR” such adoption. The Board expresses no opinion as to whether you should redeem your Public Shares in connection with the Article Amendment Proposal.
If the Article Amendment Proposal is Not Approved
If the Article Amendment Proposal is not approved by a special resolution of our shareholders, we will not offer to redeem the Public Shares held by the Public Shareholders in accordance with Article 35.11 of the Company’s Articles and we may have less flexibility to consummate the initial business combination. If the Article Amendment Proposal is not approved by a special resolution of our shareholders, Public Shareholders will retain their right to redeem their Public Shares for their pro rata portion of the funds available in the Trust Account upon consummation of a business combination, or to have their Public Shares redeemed for cash if the Company has not completed the business combination by the Termination Date.
If the Article Amendment Proposal is not approved and if the Company is unable to complete its initial business combination by December 6, 2026, the Company will (i) cease all operations except for the purpose of winding up (ii) as promptly as reasonably possible but not more than five (5) Business Days (as that term is defined in the Articles) thereafter to redeem the Public Shares to the holders of the Public Shares, on a pro rata basis, in cash at a per-share amount equal to the aggregate amount then on deposit in the Trust Account (including interest not previously released to the Company, which shall be net of taxes payable, and less interest to pay dissolution expenses) divided by the number of then outstanding Public Shares and (iii) as promptly as reasonably possible following such redemption, subject to the approval of our remaining shareholders and the Board, liquidate and dissolve the Company, subject to the Company’s obligations under the Companies Act (Revised) of the Cayman Islands, including any statutory modification or re-enactment thereof for the time being in force, to provide for claims of creditors and the requirements of other applicable law. In the event of such redemption, only the holders of the Public Shares shall be entitled to receive pro rata redeeming provisions from the Trust Account with respect to their Public Shares.
The holders of the Founder Shares and Private Units will not participate in any redemption distribution with respect to their Founder Shares or Private Units, until all of the claims of any redeeming shareholders and creditors are fully satisfied (and then only from funds held outside the trust account). The Company will pay the costs of liquidating the trust account from the up to $50,000 of interest earned on the funds held in the trust account that is available to us for liquidation expenses.
If the Article Amendment Proposal is Approved
If the Article Amendment Proposal is duly approved by a special resolution of our shareholders, Aimei Health will proceed with effecting the proposed amendment to the Articles and offer to redeem the Public Shares held by the Public Shareholders electing to be redeemed, and shall not redeem ordinary shares held by our Initial Shareholders or their affiliates or the directors or officers of the Company pursuant to such offer, whether or not such holders accept such offer, in accordance with Article 35.11 of the Articles. The Company will continue to work to consummate its initial business combination.
You are not being asked to vote on a business combination at this time. If the Article Amendment Proposal is approved and you do not elect to redeem your Public Shares, you will retain the right to vote on any proposed business combination when it is submitted to shareholders (provided that you are a shareholder on the record date for a meeting to consider a business combination) and the right to redeem your Public Shares for a pro rata portion of the Trust Account in the event such business combination is approved and completed or the Company has not consummated a business combination by the Termination Date.
If the Article Amendment Proposal is approved by a special resolution of our shareholders, the removal of the funds from the Trust Account in connection with the Election will reduce the amount held in the Trust Account following the Election. The Company cannot predict the amount that will remain in the Trust Account after such withdrawal if the Article Amendment Proposal is approved and the amount remaining in the Trust Account may be only a fraction of the amount of $12,740,939.68 (including interest but less the funds used to pay taxes) that was in the Trust Account as of the Record Date. In such event, the Company may require additional funds to complete a business combination, and there can be no assurance that such funds will be available on terms acceptable to the parties or at all.
Interests of our Sponsor, Directors, and Officers
When you consider the recommendation of the Board, you should keep in mind that our Sponsor, executive officers and members of the Board have interests that may be different from, or in addition to, your interests as a shareholder. These interests include, among other things:
| ● | The fact that our Initial Shareholders, including the Sponsor and our directors and officers, hold 1,725,000 Founder Shares and 332,000 Private Units that would expire worthless if a business combination is not consummated. The Founder Shares had an aggregate market value of approximately $20,889,750 based on the closing price for the Company’s Public Shares of $12.11 on the Nasdaq on the Record Date and the Private Units had an aggregate market value (assuming they have the same value per Unit as the Public Units) of $4,146,680 based on the closing price for the Public Units of $12.49 on the Nasdaq on the Record Date; | |
| ● | Even if the trading price of our ordinary shares lost substantial value prior to the consummation of a business combination, due to the low amount of the initial investment in the Company made by the Sponsor, if an initial business combination is completed, the Initial Shareholders are likely to be able to make a substantial profit on their investment in us even if the ordinary shares have lost significant value. On the other hand, if the Article Amendment Proposal is not approved and the Company liquidates without completing its initial business combination before December 6, 2026, the Initial Shareholders will lose their entire investment in us; | |
| ● | In order to finance transaction costs in connection with an intended initial business combination, our Sponsor, affiliates of the Sponsor, officers, and directors may, but are not obligated to, make loans from time to time to us to fund certain capital requirements (“Working Capital Loans”). Such Working Capital Loans would be evidenced by promissory notes. The notes would either be repaid upon consummation of a business combination, without interest, or, at the lender’s discretion, up to $1,500,000 of notes may be converted upon consummation of a business combination into additional Private Units at a price of $10.00 per Unit. As of June 30, 2026, there were no amounts outstanding under any Working Capital Loan; |
| ● | The Sponsor, and our officers and directors are entitled to reimbursement of out-of-pocket expenses incurred by them in connection with certain activities on our behalf, such as identifying and investigating possible business targets and business combinations. However, if the Company fails to consummate a business combination by the Termination Date, they will not have any claim against the Trust Account for reimbursement. Accordingly, Aimei Health may not be able to reimburse these expenses if the Company liquidates without completing its initial business combination before December 6, 2026 (i.e., 36 months from the closing of the IPO). As of June 30, 2026, the Sponsor, and our officers and directors did not incur any unpaid reimbursable expenses; and |
| ● | The Sponsor agreed, commencing from the date that the Company’s securities were first listed on Nasdaq, through the earlier of the Company’s consummation of a business combination and its liquidation, to make available to the Company certain general and administrative services, including office space, utilities, and administrative services, as the Company may require from time to time. The Company agreed to pay to the Sponsor, $10,000 per month, for up to 12 months, subject to extension to up to 36 months. As of June 30, 2026, the unpaid balance was $1,129,651, which was included in amount due to related party balance. |
Additionally, if the Article Amendment Proposal is approved and we consummate an initial business combination, the Sponsor, and our officers and directors may have additional interests as will be described in the proxy statement for the business combination.
The Company’s directors, executive officers, its Sponsor, and their respective affiliates are not entitled to redeem the Founder Shares or ordinary shares underlying the Private Units. In addition, Aimei Health’s directors, executive officers and their affiliates may choose to buy Units or ordinary shares of Aimei Health in the open market and/or through negotiated private purchases. In the event that purchases do occur, the purchasers may seek to purchase shares from shareholders who would otherwise have voted against the Article Amendment Proposal. Any shares of Aimei Health held by our Sponsor and its affiliates may be voted in favor of the Article Amendment Proposal.
Resolution to be Voted Upon - Article Amendment Proposal
The full text of the resolution to be passed is as follows:
“RESOLVED, as a special resolution, that with immediate effect, the Amended and Restated Articles of Association of the Company currently in effect (the “Articles”) be amended to extend the date by which the Company has to consummate a business combination from 36 months from the date of the Company’s initial public offering (namely, December 6, 2026) to 48 months from the date of the Company’s initial public offering (namely, December 6, 2027) by the deletion of the existing Article 35.2 in its entirety and the insertion of the following language in its place:
The Company has until 12 months from the closing of the IPO to consummate a Business Combination, provided however that if the board of directors anticipates that the Company may not be able to consummate a Business Combination within 12 months of the closing of the IPO, the Company may, by resolution of directors if requested by the Sponsor, extend the period of time to consummate a Business Combination up to thirty-six times, each by an additional one month (for a total of up to 48 months to complete a Business Combination), subject to the Sponsor depositing additional funds into the Trust Account in accordance with terms as set out in the trust agreement governing the Trust Account and referred to in the Registration Statement, or, if such trust agreement has been amended, in that trust agreement, as amended from time to time, in accordance with its terms. In the event that the Company does not consummate a Business Combination within 12 months from the closing of the IPO or within up to 48 months from the closing of the IPO (subject in the latter case to valid 1 month extensions having been made in each case (such date falling 12 months or up to 48 months, as applicable, after the closing of the IPO being referred to as the “Termination Date”)), such failure shall trigger an automatic redemption of the Public Shares (an “Automatic Redemption Event”) and the directors of the Company shall take all such action necessary to (i) cease all operations except for the purpose of winding up (ii) as promptly as reasonably possible but no more than five (5) Business Days thereafter to redeem the Public Shares to the holders of Public Shares, on a pro rata basis, in cash at a per-share amount equal to the applicable Per-Share Redemption Price; and (iii) as promptly as reasonably possible following such Automatic Redemption Event, subject to the approval of our remaining Members and our directors, liquidate and dissolve the Company, subject to the Company’s obligations under the Act to provide for claims of creditors and the requirements of other applicable law. In the event of an Automatic Redemption Event, only the holders of Public Shares shall be entitled to receive pro rata redeeming distributions from the Trust Account with respect to their Public Shares.”
Required Vote
Approval of the Article Amendment Proposal requires a special resolution which requires the affirmative vote of at least two-thirds of the votes cast by the shareholders, who, being present in person or represented by proxy at the Extraordinary General Meeting and entitled to vote on such matter, vote at the Extraordinary General Meeting. Abstentions and broker non-votes, which are not votes cast, will have no effect with respect to approval of this Proposal.
All of Aimei Health’s directors, executive officers and their affiliates are expected to vote any shares owned by them in favor of the Article Amendment Proposal. On the Record Date, our Sponsor and the directors and executive officers of Aimei Health and their affiliates beneficially owned and were entitled to vote 2,057,000 ordinary shares of Aimei Health representing approximately 64.96% of Aimei Health’s issued and outstanding ordinary shares. As the Article Amendment Proposal is not a “routine” matter, brokers will not be permitted to exercise discretionary voting on this proposal.
Recommendation of the Board
THE BOARD UNANIMOUSLY RECOMMENDS THAT YOU VOTE “FOR” THE ARTICLE AMENDMENT PROPOSAL. THE BOARD EXPRESSES NO OPINION AS TO WHETHER YOU SHOULD ELECT TO REDEEM YOUR PUBLIC SHARES.
Redemption Rights
If the Article Amendment Proposal is duly approved by a special resolution of our shareholders, Public Shareholders may elect to redeem their Public Shares at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest (which interest shall be net of taxes payable), divided by the number of then outstanding Public Shares. Public Shareholders who do not elect to redeem their Public Shares on the approval of the Article Amendment Proposal will retain the right to redeem their Public Shares upon consummation of a business combination, or if the Company has not completed the business combination by the Termination Date.
IN ORDER TO EXERCISE YOUR REDEMPTION RIGHTS UPON THE APPROVAL OF THE ARTICLE AMENDMENT PROPOSAL, YOU MUST, PRIOR TO 5:00 P.M. EASTERN TIME ON NOVEMBER 6, 2026 (TWO BUSINESS DAYS BEFORE THE EXTRAORDINARY GENERAL MEETING) TENDER YOUR SHARES PHYSICALLY OR ELECTRONICALLY AND SUBMIT A REQUEST IN WRITING THAT WE REDEEM YOUR PUBLIC SHARES (UPON THE APPROVAL OF THE ARTICLE AMENDMENT PROPOSAL) FOR CASH TO CONTINENTAL STOCK TRANSFER & TRUST COMPANY, OUR TRANSFER AGENT, AT THE FOLLOWING ADDRESS: CONTINENTAL STOCK TRANSFER & TRUST COMPANY, 1 STATE STREET PLAZA, 30TH FLOOR, NEW YORK, NEW YORK 10004, ATTN: SPAC REDEMPTION TEAM, E-MAIL: SPACREDEMPTIONS@CONTINENTALSTOCK.COM. THE REDEMPTION RIGHTS INCLUDE THE REQUIREMENT THAT A SHAREHOLDER MUST IDENTIFY ITSELF IN WRITING AS A BENEFICIAL HOLDER AND PROVIDE ITS LEGAL NAME, PHONE NUMBER AND ADDRESS IN ORDER TO VALIDLY REDEEM ITS PUBLIC SHARES.
Through the DWAC system, the electronic delivery process can be accomplished by the shareholder, whether or not it is a record holder or its shares are held in “street name,” by contacting the transfer agent or its broker and requesting delivery of its shares through the DWAC system. Delivering shares physically may take significantly longer. In order to obtain a physical stock certificate, a shareholder’s broker and/or clearing broker, DTC, and the Company’s transfer agent will need to act together to facilitate this request. There is a nominal cost associated with the above-referenced tendering process and the act of certificating the shares or delivering them through the DWAC system. The transfer agent will typically charge the tendering broker $100 and the broker would determine whether or not to pass this cost on to the redeeming holder. It is the Company’s understanding that shareholders should generally allot at least two weeks to obtain physical certificates from the transfer agent. The Company does not have any control over this process or over the brokers or DTC, and it may take longer than two weeks to obtain a physical stock certificate. Such shareholders will have less time to make their investment decision than those shareholders that deliver their shares through the DWAC system. Shareholders who request physical stock certificates and wish to redeem may be unable to meet the deadline for tendering their shares before exercising their redemption rights and thus will be unable to redeem their shares.
Certificates that have not been tendered in accordance with these procedures prior to 5:00 p.m. Eastern time on November 6, 2026 (two business days before the Extraordinary General Meeting) will not be redeemed, upon the approval of the Article Amendment Proposal by Special Resolution, for cash held in the Trust Account on the redemption date. In the event that a Public Shareholder tenders its shares and decides prior to the vote at the Extraordinary General Meeting that it does not want to redeem its shares, the shareholder may withdraw the tender. If you delivered your shares for redemption to our transfer agent and decide prior to the vote at the Extraordinary General Meeting not to redeem your Public Shares, you may request that our transfer agent return the shares (physically or electronically). You may make such request by contacting our transfer agent at the address listed above. In the event that a Public Shareholder tenders shares and the Article Amendment Proposal is not approved, these shares will not be redeemed and the physical certificates representing these shares will be returned to the shareholder promptly following the determination that the Article Amendment Proposal will not be approved. The transfer agent will hold the certificates of Public Shareholders that make the election until such shares are redeemed for cash or returned to such shareholders.
If properly demanded, upon the approval of the Article Amendment Proposal, the Company will redeem each Public Share for a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest (which interest shall be net of taxes payable), divided by the number of then outstanding Public Shares. Based upon the amount in the Trust Account as of the Record Date, the Company anticipates that the per-share price at which Public Shares will be redeemed from cash held in the Trust Account will be approximately $12.25. The closing price of the Company’s ordinary shares as of the Record Date was $12.11.
If you exercise your redemption rights, upon the approval of the Article Amendment Proposal, you will be exchanging your shares for cash and will no longer own the shares. You will be entitled to receive cash for these shares only if you properly demand redemption and tender your stock certificate(s) to the Company’s transfer agent prior to 5:00 p.m. Eastern time on November 6, 2026 (two business days before the Extraordinary General Meeting). The Company anticipates that a Public Shareholder who tenders shares for redemption upon approval by a special resolution of our shareholders of the Article Amendment Proposal would receive payment of the redemption price for such shares soon after the completion of the Article Amendment.
UNITED STATES FEDERAL INCOME TAX CONSIDERATIONS
The following brief discussion summarizes certain United States federal income tax considerations generally applicable to U.S. Holders (as defined below) who elect to have their ordinary shares redeemed for cash pursuant to the exercise of a right to redemption in connection with an Election.
This brief discussion is limited to certain United States federal income tax considerations to such U.S. Holders who hold ordinary shares as a capital asset under the U.S. Internal Revenue Code of 1986, as amended (the “Code”).
This discussion is a summary only and does not consider all aspects of United States federal income taxation that may be relevant to a U.S. Holder exercising its right to redemption in light of such holder’s particular circumstances, including tax consequences to U.S. Holders who are:
| ● | financial institutions or financial services entities; | |
| ● | broker-dealers; | |
| ● | taxpayers that are subject to the mark-to-market accounting rules; | |
| ● | tax-exempt entities; | |
| ● | governments or agencies or instrumentalities thereof; | |
| ● | insurance companies; | |
| ● | regulated investment companies or real estate investment trusts; | |
| ● | expatriates or former long-term residents of the United States; | |
| ● | persons that actually or constructively own five percent or more of our voting shares or five percent or more of the total value of any class of our shares; | |
| ● | persons that acquired our securities pursuant to an exercise of employee share options, in connection with employee share incentive plans or otherwise as compensation; | |
| ● | persons that hold our securities as part of a straddle, constructive sale, hedging, conversion or other integrated or similar transaction; | |
| ● | partnerships (or entities or arrangements treated as partnerships or other pass-through entities for U.S. federal income tax purposes), or persons holding our securities through such partnerships or other pass-through entities; or | |
| ● | persons whose functional currency is not the U.S. dollar. |
This brief discussion is based on the Code, proposed, temporary and final Treasury Regulations promulgated under the Code, and judicial and administrative interpretations thereof, all as of the date hereof. All of the foregoing is subject to change, which change could apply retroactively and could affect the tax considerations described herein. This discussion does not address U.S. federal taxes other than those pertaining to U.S. federal income taxation (such as estate or gift taxes, the alternative minimum tax or the Medicare tax on investment income), nor does it address any aspects of U.S. state or local or non-U.S. taxation.
We have not sought and do not intend to seek any rulings from the IRS regarding an intended Business Combination or an exercise of redemption rights by holders of our ordinary shares. There can be no assurance that the IRS will not take positions inconsistent with the considerations discussed below or that any such positions could be sustained by a court. Moreover, there can be no assurance that future legislation, regulations, administrative rulings or court decisions will not change the accuracy of the statements in this discussion.
As used herein, the term “U.S. Holder” means a beneficial owner of ordinary shares, units, or rights, who or that is for United States federal income tax purposes: (i) an individual citizen or resident of the United States, (ii) a corporation (or other entity treated as a corporation for United States federal income tax purposes) that is created or organized (or treated as created or organized) in or under the laws of the United States, any state thereof or the District of Columbia, (iii) an estate the income of which is subject to United States federal income taxation regardless of its source or (iv) a trust if (A) a court within the United States is able to exercise primary supervision over the administration of the trust and one or more U.S. persons have the authority to control all substantial decisions of the trust, or (B) it has in effect a valid election to be treated as a U.S. person.
This brief summary discussion does not consider the tax treatment of partnerships or other pass-through entities or persons who hold our securities through such entities. If a partnership (or other entity or arrangement classified as a partnership for United States federal income tax purposes) is the beneficial owner of our securities, the United States federal income tax treatment of a partner in the partnership generally will depend on the status of the partner and the activities of the partnership. Partnerships holding our securities and partners in such partnerships are urged to consult their own tax advisors.
THIS DISCUSSION IS ONLY A SUMMARY OF CERTAIN UNITED STATES FEDERAL INCOME TAX CONSIDERATIONS ASSOCIATED WITH AN ELECTION. EACH REDEEMING U.S. HOLDER IS URGED TO CONSULT ITS OWN TAX ADVISOR WITH RESPECT TO THE PARTICULAR TAX CONSEQUENCES TO SUCH U.S. HOLDER OF THE EXERCISE OF REDEMPTION RIGHTS THROUGH AN ELECTION, INCLUDING THE APPLICABILITY AND EFFECT OF ANY STATE, LOCAL, AND NON-U.S. TAX LAWS.
In the Event of a Redemption as Sale or Distribution
In the event that a U.S. Holder’s ordinary shares are redeemed pursuant to an Election, the treatment of the transaction for United States federal income tax purposes will depend on whether the redemption qualifies as a sale of the ordinary shares under Section 302 of the Code. If the redemption qualifies as a sale of ordinary shares, a U.S. Holder generally will recognize capital gain or loss and any such capital gain or loss generally will be long-term capital gain or loss if the U.S. Holder’s holding period for such ordinary shares exceeds one year. It is unclear, however, whether certain redemption rights may suspend the running of the applicable holding period for this purpose. If the redemption does not qualify as a sale of ordinary shares, it will be treated as a corporate distribution. In that case, the U.S. Holder generally will be required to include in gross income as a dividend the amount of the distribution to the extent the distribution is paid out of current or accumulated earnings and profits (as determined under United States federal income tax principles). To the extent those distributions exceed our current and accumulated earnings and profits, they will constitute a return of capital, which will first reduce your basis in our ordinary shares, but not below zero, and then will be treated as gain from the sale of our ordinary shares.
Whether a redemption pursuant to an Election qualifies for sale treatment will depend largely on the total number of our ordinary shares treated as held by the U.S. Holder relative to all of our ordinary shares outstanding both before and after such redemption. The redemption generally will be treated as a sale of the ordinary shares (rather than as a corporate distribution) if such redemption (i) is “substantially disproportionate” with respect to the U.S. Holder, (ii) results in a “complete termination” of the U.S. Holder’s interest in us or (iii) is “not essentially equivalent to a dividend” with respect to the U.S. Holder. These tests are explained more fully below.
In determining whether any of the foregoing tests are satisfied, a U.S. Holder takes into account not only our ordinary shares actually owned by the U.S. Holder, but also our ordinary shares that are constructively owned by such holder. A U.S. Holder may constructively own, in addition to shares owned directly, shares owned by certain related individuals and entities in which the U.S. Holder has an interest or that have an interest in such U.S. Holder, as well as any shares the U.S. Holder has a right to acquire by exercise of an option, which would generally include ordinary shares which could be acquired pursuant to the exercise of any warrants. In order to meet the substantially disproportionate test, the percentage of our outstanding voting shares actually and constructively owned by the U.S. Holder immediately following a redemption of ordinary shares must, among other requirements, be less than 80 percent of the percentage of our outstanding voting shares actually and constructively owned by the U.S. Holder immediately before the redemption.
Prior to a Business Combination, the ordinary shares may not be treated as voting shares for this purpose and, consequently, this substantially disproportionate test may not be applicable. There will be a complete termination of a U.S. Holder’s interest if either (i) all of our ordinary shares actually and constructively owned by the U.S. Holder are redeemed or (ii) all of our ordinary shares actually owned by the U.S. Holder are redeemed and the U.S. Holder is eligible to waive, and effectively waives in accordance with specific rules, the attribution of ordinary shares owned by certain family members and the U.S. Holder does not constructively own any other shares of ours. The redemption of the ordinary shares will not be essentially equivalent to a dividend if such redemption results in a “meaningful reduction” of the U.S. Holder’s proportionate interest in us. Whether the redemption will result in a meaningful reduction in a U.S. Holder’s proportionate interest in us will depend on the particular facts and circumstances. The IRS has indicated in a published ruling that even a small reduction in the proportionate interest of a small minority shareholder in a publicly held corporation who exercises no control over corporate affairs may constitute such a “meaningful reduction.”
If none of the foregoing tests are satisfied, then a redemption could be treated as a corporate distribution as described above. A U.S. Holder considering exercising its redemption right should consult its own tax advisor as to whether the redemption will be treated as a sale or as a corporate distribution under the Code.
Information Reporting and Backup Withholding
Dividend payments with respect to our ordinary shares and proceeds from the sale, exchange or redemption of our ordinary shares may be subject to information reporting to the IRS and possible United States backup withholding. Backup withholding will not apply, however, to a U.S. Holder who furnishes a correct taxpayer identification number and makes other required certifications, or who is otherwise exempt from backup withholding and establishes such exempt status.
Backup withholding is not an additional tax. Amounts withheld as backup withholding may be credited against a U.S. Holder’s U.S. federal income tax liability, and a U.S. Holder generally may obtain a refund of any excess amounts withheld under the backup withholding rules by timely filing the appropriate claim for refund with the IRS and furnishing any required information. U.S. Holders are urged to consult their own tax advisors regarding the application of backup withholding and the availability of and procedure for obtaining an exemption from backup withholding in their particular circumstances.
PROPOSAL 2— THE TRUST AGREEMENT AMENDMENT PROPOSAL
Aimei Health is proposing to approve an amendment to the Trust Agreement by and between the Company and Continental Stock Transfer & Trust Company governing the trust account established in connection with the Company’s IPO, to reflect the proposed extension of the timeframe within which the Company must consummate its initial business combination from 36 months from the date of the Company’s IPO to 48 months from the date of the Company’s IPO (the “Trust Amendment”). A copy of the proposed Trust Amendment is attached to this proxy statement as Annex A. All shareholders are encouraged to read the proposed amendment in its entirety for a more complete description of its terms.
Currently, under the Company’s Articles, the Company has until 12 months from the closing of its IPO (namely, until December 6, 2024) to consummate its initial business combination (“Combination Period”). The Articles and the Trust Agreement currently in effect also provide that if the Board anticipates that we may not be able to consummate our initial business combination within the Combination Period, we may, by resolution of the Board if requested by our Sponsor, extend the Combination Period up to twenty-four (24) times each for an additional one month from December 6, 2024 (i.e., 12 months after the consummation of the IPO) up to December 6, 2026 (i.e., 36 months after the consummation of the IPO), subject to the Sponsor depositing additional funds into the Trust Account in accordance with terms as set out in the trust agreement governing the Trust Account and referred to in the Registration Statement. If the Trust Agreement Amendment Proposal is approved by the shareholders, the Company will be granted an additional 12 months to consummate its business combination, thereby extending the deadline for consummating a business combination from December 6, 2026 to as late as December 6, 2027 (i.e., 48 months after the consummation of the IPO). The monthly extension fee (currently, an amount equal to the lesser of (i) $80,000 for all outstanding Public Shares and (ii) $0.033 for each outstanding Public Share) is required to be deposited into the Trust Account in accordance with the current terms of the Trust Agreement, to extend the Combination Period by one additional month.
Through this Trust Agreement Amendment Proposal, Aimei Health is seeking shareholder approval to amend the Trust Agreement to reflect the proposed extension of the period during which the Company may consummate an initial business combination from up to 36 months following the consummation of the IPO to up to 48 months following the consummation of the IPO. The Trust Amendment will not change the amount of the monthly extension fee currently required to be deposited into the Trust Account for each Monthly Extension.
The Board’s Reasons for the Trust Agreement Amendment Proposal
Under the Trust Agreement Amendment Proposal, the Company is seeking the approval of its shareholders of an amendment to the Trust Agreement that would reflect the proposed extension of the date by which the Company may consummate an initial business combination from December 6, 2026 to as late as December 6, 2027. The purpose of the Trust Agreement Amendment Proposal is to conform the Trust Agreement to the proposed amendment to the Articles contemplated by the Article Amendment Proposal and provide the Company with an additional 12 months to consummate an initial business combination. The Board believes that the Trust Agreement Amendment Proposal is necessary in order to implement the Extension contemplated by the Article Amendment Proposal and provide the Company with additional time to identify and consummate an initial business combination. Therefore, the Board has determined that it is in the best interests of the Company to give effect to the proposed amendment to the Trust Agreement and recommends our shareholders approve and adopt the Trust Agreement Amendment Proposal.
If the Trust Agreement Amendment Proposal is Not Approved
If the Trust Agreement Amendment Proposal is not approved, the Trust Agreement will not be amended to reflect the proposed extension of the period within which the Company may consummate an initial business combination from up to 36 months following the consummation of the IPO to up to 48 months following the consummation of the IPO. Accordingly, the Company will not be able to effect the Extension contemplated by the Trust Agreement Amendment Proposal.
If the Trust Agreement Amendment Proposal is Approved
If the Trust Agreement Amendment Proposal is approved, the Company and the Trustee will enter into the Trust Amendment substantially in the form attached hereto as Annex A, pursuant to which the Trust Agreement will be amended to reflect the extension of the period within which the Company may consummate an initial business combination from up to 36 months following the consummation of the IPO to up to 48 months following the consummation of the IPO, or until December 6, 2027. The Trust Amendment will not modify the amount of the Monthly Extension Fee currently required for each Monthly Extension. Each subsequent Monthly Extension Fee must be deposited into the Trust Account by the sixth of each succeeding month to effect each additional Monthly Extension until November 6, 2027. The Company will then continue to work to consummate its initial business combination.
You are not being asked to vote on a business combination at this time.
Resolution to be Voted Upon - Trust Agreement Amendment Proposal
The full text of the resolution to be passed is as follows:
“RESOLVED, as an ordinary resolution, that, the amendment to the Trust Agreement to reflect the extension of the date by which the Company has to consummate a business combination from 36 months from the date of the Company’s initial public offering to 48 months from the date of the Company’s initial public offering, be and is hereby approved and adopted.”
Required Vote
Approval of the Trust Agreement Amendment Proposal requires the affirmative vote of a simple majority of the votes cast by the shareholders who, being present in person or by proxy and entitled to vote at the Extraordinary General Meeting, vote at the Extraordinary General Meeting. Abstentions and broker non-votes, which are not votes cast, will have no effect with respect to approval of this Proposal.
All of Aimei Health’s directors, executive officers and their affiliates are expected to vote any shares owned by them in favor of the Trust Agreement Amendment Proposal. On the Record Date, our Sponsor and the directors and executive officers of Aimei Health and their affiliates beneficially owned and were entitled to vote 2,057,000 ordinary shares of Aimei Health representing approximately 64.96% of Aimei Health’s issued and outstanding ordinary shares. As the Trust Agreement Amendment Proposal is not a “routine” matter, brokers will not be permitted to exercise discretionary voting on this proposal.
Recommendation of the Board
The Board considered the conflicts, as described in “The Article Amendment Proposal — Interests of our Sponsor, Directors, and Officers”, between their respective personal pecuniary interests in successfully completing a business combination and the interests of Public Shareholders. The Board determined that their respective personal pecuniary interests, in the form of the contingent and hypothetical value of ordinary shares if a business combination is ultimately completed, was substantially less than the additional time, effort and potential liability they might incur if they failed to discharge their fiduciary duties to the Company’s shareholders to the best of their ability, which they, as shareholders as well, share.
After careful consideration of all relevant factors, the Board determined that the Trust Agreement Amendment Proposal is fair to, and in the best interests of, the Company and its shareholders, and has declared them advisable.
THE BOARD UNANIMOUSLY RECOMMENDS THAT YOU VOTE “FOR” THE TRUST AGREEMENT AMENDMENT PROPOSAL.
PROPOSAL NO. 3 — THE AUDITOR APPOINTMENT PROPOSAL
Overview
The Auditor Appointment Proposal is asking the shareholders to approve the engagement of MaloneBailey, LLP (“MaloneBailey”) to serve as the Company’s independent registered public accounting firm for the year ending December 31, 2026. If our shareholders do not approve the selection of MaloneBailey as our independent registered public accounting firm for the fiscal year ending December 31, 2026, our audit committee may reconsider the selection of MaloneBailey as our independent registered public accounting firm.
MaloneBailey has served as the Company’s independent registered public accounting firm since 2023. MaloneBailey has audited our financial statements for the years ended December 31, 2024 and 2025.
Fees Paid to the Independent Registered Public Accounting Firm
The following is a summary of fees paid or to be paid to MaloneBailey, for services rendered.
Audit Fees. Audit fees consist of fees for professional services rendered for the audit of our year-end financial statements and services that are normally provided by MaloneBailey in connection with regulatory filings. The aggregate fees of MaloneBailey for professional services rendered for the audit of our annual financial statements, review of the financial information included in our Forms 10-Q for the respective periods and other required filings with the SEC totaled approximately $160,000 for the year ended December 31, 2024 and $130,000 for the year ended December 31, 2025. The above amounts include interim procedures and audit fees, as well as attendance at audit committee meetings.
Audit-Related Fees. Audit-related fees consist of fees billed for assurance and related services that are reasonably related to performance of the audit or review of our financial statements and are not reported under “Audit Fees.” These services include attest services that are not required by statute or regulation and consultations concerning financial accounting and reporting standards. For the years ended December 31, 2024 and 2025, we did not pay MaloneBailey any audit-related fees.
Tax Fees. We have not paid MaloneBailey any fee for tax return services, planning and tax advice for the years ended December 31, 2024 and 2025.
All Other Fees. We did not pay MaloneBailey for any other services for the years ended December 31, 2024 and 2025.
Audit Committee Policy on Pre-Approval of Audit and Permissible Non-Audit Services of Independent Registered Public Accounting Firm
Our audit committee was formed upon the consummation of our IPO. As a result, the audit committee did not preapprove all of the foregoing services, although any services rendered prior to the formation of our audit committee were approved by our board of directors. Since the formation of our audit committee, and on a going-forward basis, the audit committee has and will preapprove all auditing services and permitted non-audit services to be performed for us by our auditors, including the fees and terms thereof (subject to the de minimis exceptions for non-audit services described in the Exchange Act which are approved by the audit committee prior to the completion of the audit).
You are not being asked to vote on a business combination at this time.
Resolution to be Voted Upon – Auditor Appointment Proposal
The full text of the resolution to be passed is as follows:
“RESOLVED, as an ordinary resolution that, the engagement of MaloneBailey, LLP to serve as the Company’s independent registered public accounting firm for the year ending December 31, 2026, be confirmed, adopted, approved and ratified in all respects.”
Required Vote
Approval of the Auditor Appointment Proposal requires the affirmative vote of a simple majority of the votes cast by the shareholders who, being present in person or by proxy and entitled to vote at the Extraordinary General Meeting, vote at the Extraordinary General Meeting. Abstentions will have no effect with respect to approval of this Auditor Appointment Proposal.
Recommendation
The Board considered the conflicts, as described in “The Article Amendment Proposal — Interests of our Sponsor, Directors, and Officers”, between their respective personal pecuniary interests in successfully completing a business combination and the interests of Public Shareholders. The Board determined that their respective personal pecuniary interests, in the form of the contingent and hypothetical value of ordinary shares if a business combination is ultimately completed, was substantially less than the additional time, effort and potential liability they might incur if they failed to discharge their fiduciary duties to the Company’s shareholders to the best of their ability, which they, as shareholders as well, share.
After careful consideration of all relevant factors, the Board determined that the Auditor Appointment Proposal is fair to, and in the best interests of, the Company and its shareholders, and has declared them advisable.
THE BOARD RECOMMENDS THAT YOU VOTE “FOR” THE AUDITOR APPOINTMENT PROPOSAL.
PROPOSAL 4 — THE ADJOURNMENT PROPOSAL
The Adjournment Proposal, if adopted, will request the chairman of the Extraordinary General Meeting (who has agreed to act accordingly) to adjourn the Extraordinary General Meeting to a later date or dates to permit further solicitation of proxies. The Adjournment Proposal will only be presented to our shareholders in the event, based on the tabulated votes, there are not sufficient votes at the time of the Extraordinary General Meeting for, or otherwise in connection with, the approval of the foregoing proposals. If the Adjournment Proposal is not approved by our shareholders, it is agreed that the chairman of the Extraordinary General Meeting shall not adjourn the Extraordinary General Meeting to a later date in the event, based on the tabulated votes, there are not sufficient votes at the time of the Extraordinary General Meeting for, or otherwise in connection with, the approval of the foregoing proposals.
Resolution to be Voted Upon - Adjournment Proposal
The full text of the resolution to be passed is as follows:
“RESOLVED, as an ordinary resolution that, the chairman may adjourn the Extraordinary General Meeting to a later date or dates to permit further solicitation of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of the foregoing proposals, to be determined by the chairman of the Extraordinary General Meeting, be confirmed, adopted, approved and ratified in all respects.”
Required Vote
The approval of a simple majority of the votes cast by the shareholders who, being present in person or by proxy and entitled to vote at the Extraordinary General Meeting, vote at the Extraordinary General Meeting will be required to direct the chairman of the Extraordinary General Meeting to adjourn the Extraordinary General Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies if, based upon the tabulated vote at the time of the Extraordinary General Meeting, there are not sufficient votes for, or otherwise in connection with, the approval of the Article Amendment Proposal, the Trust Agreement Amendment Proposal, or the Auditor Appointment Proposal. Abstentions will have no effect with respect to approval of this Adjournment Proposal.
Recommendation
THE BOARD RECOMMENDS THAT YOU VOTE “FOR” THE ADJOURNMENT PROPOSAL.
DELIVERY OF DOCUMENTS TO SHAREHOLDERS
Pursuant to the rules of the SEC, Aimei Health and its agents that deliver communications to its shareholders are permitted to deliver to two or more shareholders sharing the same address a single copy of Aimei Health’s proxy statement. Upon written or oral request, Aimei Health will deliver a separate copy of the proxy statement to any shareholder at a shared address who wishes to receive separate copies of such documents in the future. Shareholders receiving multiple copies of such documents may likewise request that Aimei Health deliver single copies of such documents in the future. Shareholders may notify Aimei Health of their requests by calling or writing Aimei Health at its principal executive offices at 10 East 53rd Street, Suite 3001, New York, NY 10022, +86 13758131392.
WHERE YOU CAN FIND MORE INFORMATION
Aimei Health files annual, quarterly, and current reports, proxy statements and other information with the SEC as required by the Exchange Act. Aimei Health files its reports, proxy statements and other information electronically with the SEC. You may access information on Aimei Health at the SEC website at http://www.sec.gov.
This proxy statement describes the material elements of relevant contracts, exhibits and other information attached as annexes to this proxy statement. Information and statements contained in this proxy statement are qualified in all respects by reference to the copy of the relevant contract or other document included as an annex to this document.
You may obtain this additional information, or additional copies of this proxy statement, at no cost, and you may ask any questions you may have about the Proposals to be presented at the Extraordinary General Meeting by contacting us at the following address, telephone number or email:
Aimei Health Technology Co., Ltd
10 East 53rd Street, Suite 3001
New York, NY 10022
Attn: Junheng Xie
+86 13758131392 Email: xiejunheng@aimeihealth.com
In order to receive timely delivery of the documents in advance of the Extraordinary General Meeting, you must make your request for information no later than November 3, 2026 (one week before the date of the Extraordinary General Meeting).
Annex A
THIRD AMENDMENT
TO THE
INVESTMENT MANAGEMENT TRUST AGREEMENT
This Third Amendment (this “Amendment”) to the Trust Agreement (as defined below) is made and entered into as of __________, 2026, by and between Aimei Health Technology Co., Ltd (the “Company”) and Continental Stock Transfer & Trust Company, as trustee (“Trustee”). All terms used but not defined herein shall have the meanings assigned to them in the Trust Agreement.
WHEREAS, the Company and the Trustee have entered into that certain Investment Management Trust Agreement, dated December 1, 2023 (the “Trust Agreement” or “Original Agreement”);
WHEREAS, the Company and the Trustee have entered into that certain First Amendment to Investment Management Trust Agreement, dated February 6, 2025 (the “First Amendment”);
WHEREAS, the Company and the Trustee have entered into that certain Second Amendment to Investment Management Trust Agreement, dated December 2, 2025 (the “Second Amendment,” together with the Original Agreement and First Amendment, the “Amended Trust Agreement”);
WHEREAS, the parties hereto now desire to amend the Amended Trust Agreement as set forth herein;
WHEREAS, Section 1(i) of the Amended Trust Agreement sets forth the terms that govern the liquidation of the Trust Account under the circumstances described therein; and
WHEREAS, at an extraordinary general meeting of the Company held on November 10, 2026, the Company’s shareholders approved a proposal to amend the Amended Trust Agreement to extend the deadline for consummating a business combination from 36 months from the date of the Company’s initial public offering to 48 months from the date of the Company’s initial public offering.
NOW THEREFORE, IT IS AGREED:
| 1. | Section 1(i) of the Amended Trust Agreement is hereby amended and restated in its entirety as follows: |
| “(i) Commence liquidation of the Trust Account only after and promptly after receipt of, and only in accordance with, the terms of a letter (“Termination Letter”), in a form substantially similar to that attached hereto as either Exhibit A or Exhibit B, as applicable, signed on behalf of the Company by its President, Chief Executive Officer or Chairman of the Board and Secretary or Assistant Secretary and, in the case of a Termination Letter in a form substantially similar to that attached hereto as Exhibit A, acknowledged and agreed to by the Representative, and complete the liquidation of the Trust Account and distribute the Property in the Trust Account, including interest earned not previously released to the Company to pay its taxes payable or owed (and, in the case of Exhibit B, less up to 50,000 of interest that may be released to the Company to pay dissolution expenses), only as directed in the Termination Letter and the other documents referred to therein; provided, however, that (x) in the event that a Termination Letter has not been received by the Trustee by the 12-month anniversary of the closing of the IPO (“Closing”) or, in the event that the Company extended the time to complete the Business Combination for up to 48 months from the closing of the IPO by depositing an amount equal to the lesser of (i) $80,000 for all remaining public shares and (ii) $0.033 for each outstanding public share, for each one-month extension, but has not completed the Business Combination within the applicable monthly anniversary of the Closing (“Last Date”), or (y) upon the end of a 30-day cure period after the date any additional amount of funds was required to be deposited in the Trust Account as a condition of any extension of the Last Date approved by the Company’s shareholders, the Trust Account shall be liquidated by the Trustee in accordance with the procedures set forth in the Termination Letter attached as Exhibit B or similar hereto (net of taxes payable or owed and less up to $50,000 of interest that may be released to the Company to pay dissolution expenses) and distributed to the Public Shareholders as of the Last Date.” |
| 2. | Exhibit D of the Amended Trust Agreement is hereby amended and restated in its entirety as follows: |
[Letterhead of Company]
[Insert date]
Continental Stock Transfer & Trust Company
1 State Street, 30th Floor
New York, N.Y. 10004
Attn: Francis Wolf and Celeste Gonzalez
| Re: | Trust Account — Extension Letter |
Dear Mr. Wolf and Ms. Gonzalez:
Pursuant to Section 1(l) of the Investment Management Trust Agreement dated December 1, 2023 between Aimei Health Technology Co., Ltd. (“Company”) and Continental Stock Transfer & Trust Company, as amended (the “Trust Agreement”), this is to advise you that the Company is extending the time available in order to consummate a Business Combination with the Target Businesses for an additional one (1) month, from _______ to _________ (the “Extension”).
This Extension Letter shall serve as the notice required with respect to Extension prior to the Applicable Deadline. Capitalized words used herein and not otherwise defined shall have the meanings ascribed to them in the Trust Agreement.
In accordance with the terms of the Trust Agreement, we hereby authorize you to deposit $[ ] for all remaining public shares, which will be wired to you, into the Trust Account investments upon receipt.
This is the ____ of up to thirty-six Extension Letters.
Very truly yours,
AIMEI HEALTH TECHNOLOGY CO., LTD
| By: | ||
| Name: | Junheng Xie | |
| Title: | Chief Executive Officer |
cc: Spartan Capital Securities, LLC
| 3. | All other provisions of the Original Agreement shall remain unaffected by the terms hereof. |
| 4. | This Amendment may be signed in any number of counterparts, each of which shall be an original and all of which shall be deemed to be one and the same instrument, with the same effect as if the signatures thereto and hereto were upon the same instrument. A facsimile signature or electronic signature shall be deemed to be an original signature for purposes of this Amendment. |
| 5. | This Amendment is intended to be in full compliance with the requirements for an Amendment to the Trust Agreement as required by Section 7(c) of the Trust Agreement, and every defect in fulfilling such requirements for an effective amendment to the Trust Agreement is hereby ratified, intentionally waived and relinquished by all parties hereto. |
| 6. | This Amendment shall be governed by and construed and enforced in accordance with the laws of the State of New York, without giving effect to conflicts of law principles that would result in the application of the substantive laws of another jurisdiction. |
[Signature Page Follows]
IN WITNESS WHEREOF, the parties have duly executed this Amendment to the Trust Agreement as of the date first written above.
CONTINENTAL STOCK TRANSFER & TRUST COMPANY, as Trustee
| By: | ||
| Name: | Francis Wolf | |
| Title: | Vice President |
AIMEI HEALTH TECHNOLOGY CO., LTD
| By: | ||
| Name: | Junheng Xie | |
| Title: | Chief Executive Officer |
